✓Nov 3 session - Last update: Nov 3, 2026, 4:48 PM ET
🛡Material / Earnings✓High confidence
Source: daily_prices:fmp_change_percent
Changes History →Pre-market · Regular session opens 9:30 AM ET
Last update: Nov 3, 2026, 6:18 PM ETMarket closed·110 changes confirmed today
Track the stock moves that actually matter.
BestStocks detects meaningful changes across price, volume, earnings, filings, valuation, analyst revisions, and risk signals — and shows you the evidence behind each one.
1,000 equities monitored14 signal typesCross-checked against SEC EDGARMedian detection lag ~41s
Investment research built around change detection.
Showing:
BestStocks identifies what changed across companies and sectors, explains why it matters, and helps investors spot opportunities worth investigating.
✓Nov 2 session - Last update: Nov 2, 2026, 10:08 AM ET
🏆Material / Earnings✓High confidence
What changed: Regal Rexnord Corporation (RRX) reported EPS of $3.74 vs. consensus estimate of $2.65, beating by 41.1% on 2026-11-03.
Source: earnings_events
Changes History →What's next
What to watch
Monitor for any management commentary on 2026 guidance or demand trends in industrial end-markets during the earnings call.
✓Nov 3 session - Last update: Nov 3, 2026, 10:08 AM ET
🏆Material / Earnings✓High confidence
What changed: Gartner, Inc. (IT) reported EPS of $3.59 vs. consensus estimate of $2.84, beating by 26.4%.
Source: earnings_events
Changes History →What's next
What to watch
Next earnings scheduled for February 2, 2027, with consensus EPS estimate of $3.92.
✓Nov 3 session - Last update: Nov 3, 2026, 4:44 PM ET
⚡Material / Earnings✓High confidence
What changed: Core Scientific, Inc. (CORZ) moved +12.39% from $12.67 to $14.24 on 2026-11-03. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was 1.5x the 5-day average, modestly elevated, and earnings are scheduled to be announced on 2026-11-05 with a consensus EPS estimate of −$0.05.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Monitor Core Scientific's earnings report on 2026-11-05 for actual EPS vs. the −$0.05 consensus estimate and any forward guidance or operational updates.
✓Nov 3 session - Last update: Nov 3, 2026, 4:43 PM ET
⚠️Material / Earnings✓High confidence
What changed: The Mosaic Company (MOS) reported EPS of −$0.19 vs. consensus estimate of −$0.01, missing expectations by 1,656%.
Source: earnings_events
Changes History →What's next
What to watch
Monitor MOS's next earnings report and any guidance updates on fertilizer pricing and demand trends.
✓Nov 3 session - Last update: Nov 3, 2026, 4:38 PM ET
⚠️Material / Earnings✓High confidence
What changed: Mirum Pharmaceuticals, Inc. (MIRM) reported EPS of −$0.87 vs. consensus estimate of −$0.49, missing by 78.7% on 2026-11-03.
Source: earnings_events
Changes History →What's next
What to watch
MIRM's next earnings are scheduled for 2027-02-24, with consensus EPS estimate of −$0.58.
✓Nov 3 session - Last update: Nov 3, 2026, 4:38 PM ET
🏆Material / Earnings✓High confidence
What changed: Fortune Brands Innovations, Inc. (FBIN) reported EPS of $1.14 vs. $0.74 consensus estimate for Q3 FY2026, beating expectations by 54.3%.
Source: earnings_events
Changes History →What's next
What to watch
Investor focus will likely turn to FBIN's forward guidance and whether management signals sustained earnings momentum or attributes the beat to one-time factors.
✓Nov 3 session - Last update: Nov 3, 2026, 4:38 PM ET
🏆Material / Earnings✓High confidence
What changed: Everus Construction Group, Inc. (ECG) reported EPS of $1.79 vs. $1.31 estimate, beating consensus by 36.6% on 2026-11-03.
Source: earnings_events
Changes History →What's next
What to watch
Monitor ECG's next earnings report and any management guidance updates for confirmation of sustained profitability.
✓Nov 3 session - Last update: Nov 3, 2026, 4:38 PM ET
🏆Material / Earnings✓High confidence
What changed: Corcept Therapeutics Incorporated (CORT) reported EPS of $1.01 vs. consensus estimate of $0.79, beating by 27.2% on November 3, 2026.
Source: earnings_events
Changes History →What's next
What to watch
Monitor CORT's next quarterly earnings report and any guidance updates on sales trends for its Cushing's syndrome franchise.
✓Nov 3 session - Last update: Nov 3, 2026, 4:38 PM ET
🏆Material / Earnings✓High confidence
What changed: Assurant, Inc. 5.25% Subordinat (AIZN) reported EPS of $6.46 vs. consensus estimate of $4.75, beating consensus by 36.0%.
Source: earnings_events
Changes History →What's next
What to watch
AIZN earnings scheduled for 2027-02-09 with consensus EPS estimate of $5.40.
✓Nov 3 session - Last update: Nov 3, 2026, 4:38 PM ET
⚠️Material / Earnings✓High confidence
What changed: Omega Healthcare Investors, Inc. (OHI) reported EPS of $0.27 for Q3 FY2026 versus a consensus estimate of $0.47, missing by 42.5% on 2026-11-03.
Source: earnings_events
Changes History →What's next
What to watch
Monitor OHI's Q3 earnings call and full 10-Q filing for management commentary on what drove the miss and guidance for Q4 FY2026 and beyond.
✓Nov 3 session - Last update: Nov 3, 2026, 4:38 PM ET
⚠️Material / Earnings✓High confidence
What changed: Toast, Inc. (TOST) reported Q3 FY2026 EPS of $0.29, missing consensus estimate of $0.36 by 20.1%.
Source: earnings_events
Changes History →What's next
What to watch
Monitor Toast's 2026 guidance and any management commentary on margin pressures or customer retention trends in the next earnings call.
Latest research
View all research →In-depth equity research from the BestStocks desk — earnings breakdowns, valuation deep dives, and sector analysis behind the changes we detect.
Stock AnalysisOctober 30, 2026 · 12 min read
Reddit (RDDT) Crashes ~30% After a Q3 Beat on a Google AI Search-Traffic Warning
Reddit crashed about 30% to roughly $90.79 on October 30 — a striking reaction, because the quarter itself was strong: revenue of $895 million rose 53% year over year, a clear beat, with net income of $283 million, diluted EPS of $1.40 and adjusted EBITDA of $402 million. The stock cratered on what management said about the future. On the earnings call, CEO Steve Huffman warned that search referrals fell more than a million per week on average in October as Google answers more queries with AI, and that daily active users (around 130 million) could fall a low-double-digit percentage in the fourth quarter if the trend held. Investors also fixed on a 2% year-over-year decline in US daily actives — Reddit's most valuable market, where revenue per user is more than five times the international level — and on fourth-quarter revenue guidance of $1.00–$1.03 billion that came in below expectations; Citizens downgraded the stock before the open. The one bullish counterweight was monetization: revenue per user still jumped 36% globally. The move was company-specific — Reddit's roughly 30% drop was about four times the moves of social peers Snap and Pinterest (each down ~7%), on a day the broad market fell about 2%. After the crash Reddit trades at roughly 14 times forward earnings with about $3 billion of net cash — not expensive for 50%-plus growth, if the growth is durable. The whole debate is whether rising revenue per user can keep outrunning a top of the funnel that AI search is draining.
RDDTRead →
Stock AnalysisOctober 20, 2026 · 10 min read
General Motors (GM) Falls ~8% Despite a Q3 Beat and a $20B Buyback
General Motors fell about 8% to roughly $75.77 on October 20 — a striking reaction, because GM beat on third-quarter earnings, raised its full-year profit outlook and announced a $20 billion buyback. Adjusted earnings of $3.70 a share topped estimates on revenue of about $50 billion, and GM lifted the midpoint of its full-year adjusted-EPS guidance to about $13.25 (from $13.00) and raised its free-cash-flow outlook. The stock fell anyway on what the guidance implied, not the quarter. The full-year outlook implies a softer fourth quarter — only about $2.7 billion of operating profit versus $4.1 billion in the third, as a Silverado/Sierra redesign temporarily cuts truck deliveries by roughly 35,000 units — the raised $13.25 EPS midpoint still landed just below the roughly $13.41 the Street expected, and management flagged about $2 billion of 2026 cost inflation plus a conditional scenario of more in 2027. Two things that look like culprits mostly were not: the 62% drop in EV sales was already known and reflects a distorted 2025 comparison, and tariff costs are now expected near the low end of an existing range. Crucially, GM did not cut its 2027 outlook — it still expects next year to improve if conditions hold. The move was clearly company-specific — Ford fell only about 1%, Stellantis was flat and the S&P 500 rose — so this was a repricing of GM's forward earnings, not an auto-sector sell-off. The valuation captures the tension: GM trades at barely five to six times the forward earnings it guides to, extraordinarily cheap, because the market prices automakers for the downturn, not the peak. A $20 billion buyback into that multiple is powerfully accretive if earnings hold — but whether they hold in 2027 is exactly the question. Analysts keep a Buy consensus and an average target near $104.
GMRead →
Stock AnalysisOctober 19, 2026 · 10 min read
Summit Therapeutics (SMMT) Jumps ~6% on a New Ivonescimab Kidney-Cancer Trial
Summit Therapeutics rose about 6% to roughly $15.57 on October 19 after announcing it had opened a global Phase II trial of ivonescimab — its closely watched lead drug — in previously untreated advanced clear cell kidney cancer, with partner Akeso. The key nuance: this is the opening of a mid-stage study, not a data readout, so it is an incremental catalyst that expands the story rather than one that proves it. Summit is effectively a one-drug company: ivonescimab is a PD-1/VEGF bispecific antibody, licensed from China's Akeso, that outperformed Merck's Keytruda in a Chinese lung-cancer trial — nearly doubling progression-free survival and, in updated data, delivering a significant overall-survival benefit (30.8 vs 22.6 months) — though the global trial behind its U.S. filing has yet to formally confirm that survival benefit in Western patients. With no product revenue and a market value above $12 billion, essentially all of Summit's worth is the market's bet on that drug, so a new indication is a fresh call option on the thesis. Two bigger items frame it: AstraZeneca agreed in late September to invest about $2 billion in Summit equity (a ~12% stake), transforming the balance sheet and removing the financing overhang, and the FDA has a November 14, 2026 decision date on ivonescimab in EGFR-mutated lung cancer — a near-term, binary catalyst that matters far more than a trial start. Monday's move was partly company-specific and partly a tailwind: biotech broadly rallied, with the sector ETF up about 2.5%, but Summit outperformed. The risks are a binary valuation on one molecule, an unconfirmed Western survival benefit, and a stock down roughly 47% from its high. Analysts carry a Buy consensus and an average target near $30, inside a wide range from about $12 to the mid-$40s.
SMMTRead →
Stock AnalysisOctober 16, 2026 · 9 min read
Alcoa (AA) Jumps ~7% as a Strong Q3 Meets a Tight Aluminum Market
Alcoa rose about 7% to roughly $43.20 on October 16, in the first full session after reporting third-quarter results after the close on October 15. Two forces drove it. First, a genuine earnings beat: adjusted earnings of about $1.82 a share topped the roughly $1.54 expected, with net income of $483 million and free cash flow of $472 million, powered by record production, the completed Alumar smelter restart, and higher alumina prices that offset lower aluminum prices and higher carbon costs — though revenue of about $3.7 billion slightly missed and adjusted EBITDA fell sequentially. Second, and just as important, a broad bid for aluminum stocks on a tightening-supply narrative: peers Century Aluminum (+4.5%) and Kaiser Aluminum (+2.4%) and the materials sector (+1.5%) all rose while the market was flat, so Alcoa led a group move rather than rallying alone — a point underscored by Barclays' Overweight initiation two days earlier citing constrained supply through 2026. Alcoa is a cheap, high-beta cyclical, trading around 7 times earnings and still about 49% below its intra-year high, with earnings that swing on volatile metal prices and a tariff overhang. Analysts carry a Buy consensus and an average target near $60, so the debate is less about execution — which was strong — than about where aluminum prices and trade policy go next.
AARead →
Stock AnalysisOctober 13, 2026 · 10 min read
Johnson & Johnson (JNJ) Falls ~6% Despite a Q3 Beat-and-Raise
Johnson & Johnson fell about 6% to roughly $247.63 on October 13 after third-quarter results — an unusually large move for a defensive Dow stalwart with a beta near 0.21. The strange part: at the headline it was a beat-and-raise. Adjusted earnings of $2.59 topped estimates and the company raised full-year guidance, lifting adjusted EPS to about $11.10 at the midpoint and putting sales on track to cross $100 billion for the first time. The stock fell anyway, and the main reason was the device business: MedTech sales of about $8.6 billion grew just 2.5% and missed Wall Street's estimate for a second straight quarter, against a strong 7.9% for the Innovative Medicine drug division. On top of that, the guidance raise was modest, the adjusted 'beat' was still down about 7.5% from a year earlier, and the stock had run up about 30% over the past year, leaving it priced for good news. A separate, largely accounting story grabbed headlines: reported GAAP net income collapsed to about $210 million (EPS of $0.09) on roughly $7.6 billion of special charges, about $5.5 billion of it a talc-litigation provision — but that settlement had been announced back in July, so the quarter merely booked the charge rather than breaking news. Pharma peers and the market barely moved, confirming a company-specific drop. The trailing P/E near 30 looks alarming but is distorted by the charges; on adjusted earnings the stock trades closer to 22 times forward. Analysts keep a Buy consensus with an average target near $280, above the price.
JNJRead →
Stock AnalysisOctober 12, 2026 · 10 min read
IonQ (IONQ) Falls ~9% on a $1.3B All-Stock Cybersecurity Acquisition
IonQ fell about 9% to roughly $36 on October 12 on a day it announced a definitive agreement to acquire Elisity, a zero-trust cybersecurity company, in an all-stock deal worth up to $1.3 billion. The counterintuitive part is the point: a stock dropping on its own acquisition. The all-stock structure is why — IonQ's share count is already up about 50% over the past year as it funds an acquisition-and-fundraising spree largely with stock, and Elisity is its third billion-dollar-scale deal in roughly 16 months, after the mostly-stock Oxford Ionics purchase and the cash-and-stock SkyWater acquisition. The strategic logic is forward-looking (pairing post-quantum cryptography with Elisity's zero-trust platform to sell 'quantum-era' security), but the market read the news as more dilution and more strategic sprawl from a pre-profit company valued near $14 billion on just $246 million of revenue — about 58 times sales, with an operating margin near negative 380%. A sign of company-specific pressure: IonQ fell about 9% while quantum peers Rigetti and D-Wave fell closer to 5.5% and the Nasdaq-100 slipped under 1% — more than the sector alone would explain. Wall Street stays overwhelmingly bullish on the long-term quantum roadmap — a Strong Buy consensus with an average target far above the price — which is exactly why a story stock like this swings so violently on news.
IONQRead →